Business Wire

Kinesso Appoints Four New Regional CEOs

23.5.2022 15:04:00 EEST | Business Wire | Press release

Share

Kinesso, IPG’s connected intelligence company, today announced the appointment of four new Regional CEOs. Executives previously in Matterkind leadership roles are being promoted to Kinesso Regional CEOs and will retain their Matterkind leadership responsibilities as well: Matt Ware in APAC, Andy Butters in EMEA, Jorge Chavez in LATAM, and Sean Muzzy in North America. Each will be responsible for ensuring clients have a single, simplified engagement experience with Kinesso and Matterkind, companies that work closely together as part of the data, technology, and media activation backbone for IPG.

The Regional CEO role was created to streamline support for Kinesso’s largest IPG partner, Mediabrands, and to capitalize on growth opportunities as Kinesso continues to evolve its business both inside and outside the IPG network. By appointing leaders who were already in region, Kinesso is building on the strength of Matterkind’s existing international leadership team, all of whom are well positioned to spearhead the design and delivery of integrated solutions across the breadth of Kinesso’s and Matterkind’s offerings.

“Putting Regional CEOs in place supports the kind of horizontal integration that will spark additional innovation at Kinesso,” said Arun Kumar, Chief Data and Technology Officer at IPG and Global CEO at Kinesso. “Innovation happens everywhere. Matt, Andy, Jorge, and Sean will give us a unified, global focus on the challenges we need to solve for our clients – including better connections between their martech and adtech – and will surely be a catalyst for further growth for Kinesso and our clients.”

“I couldn’t be more thrilled for Matt, Andy, Jorge and Sean,” said Erica Schmidt, Global CEO at Matterkind. “They already have a track record of success leading Matterkind’s business in these regions, and I know they will continue to deliver excellence in their new roles.”

The Regional CEOs will serve as a single point of contact for Kinesso and Matterkind services and solutions. Clients will benefit from the end-to-end solution sets and additional innovations Kinesso and Matterkind develop as they work more cross-functionally and globally.

Kinesso’s new Regional CEOs’ bios can be found here.

About Kinesso

Kinesso is a connected intelligence company that builds applications and software solutions, working with agencies and partners to deliver consistent and relevant customer experiences for people across all channels. Kinesso’s technology solutions and services span audience, planning, and activation, delivering insights that drive growth for leading global brands. Kinesso is part of The Interpublic Group of Companies, Inc. (IPG). For more information, visit kinesso.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lanie Miller Jones
lanie.millerjones@kinesso.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 05:00:00 EEST | Press release

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and

Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 02:51:00 EEST | Press release

Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women’s health, the company’s portfolio includes more than 70 products across Women’s Health and General Medicines, which includes biosimila

PMC Organometallix Announces Price Increase on All Products25.4.2026 00:02:00 EEST | Press release

Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli

Frankfurt Higher Regional Court upholds BESREMi ® arbitral award in favor of AOP Health24.4.2026 19:52:00 EEST | Press release

Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into

Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 17:37:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be entitled to benefits including enhanced communications and a shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA’s rigorous safety and efficacy standards. “We are honored and grateful to be selected for the CNPV which is a clear validation of both the urgent unmet need facing millions of people living with treatment resistant depression and the innovative science of COMP360,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “As the most advan

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye